NCT06162195View on ClinicalTrials.gov

The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2035

Conditions
Osteoarthritis, HipInflammatory Arthritis
Interventions
DEVICE

The H1 Implant

Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.

DEVICE

Cementless total hip replacement

Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement

All Listed Sponsors
collaborator

Imperial College London

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

Embody Orthopaedic Limited

INDUSTRY

NCT06162195 - The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement | Biotech Hunter | Biotech Hunter